Clinical Trials Logo

Clinical Trial Summary

The aim of the study was to calculate sensitivity, and accuracy of ultrasound guided percutaneous core needle biopsy in different thoracic tumors (lung, pleural, chest wall and mediastinal).


Clinical Trial Description

Peripheral intrathoracic shadows are common presentation of different diseases of different origin (chest wall, pleura, pulmonary, and mediastinum), they are increasing in numbers including, peripheral lung cancer, tuberculosis, pneumonia, and atelectasis. [1] Thoracic masses with wall contact represent a frequent pathology that requires complex imaging studies, and often interventional procedures, in order to reach the complete diagnosis. In most cases, after a thoracic lesion is found on a thoracic X-Ray, the next step is to perform a CT and/or a bronchoscopy exam, but pleural and pulmonary lesions often call for additional investigations. Therefore, transthoracic ultrasonography (US) permits visualization of these lesions, their structural characterization, while offering suggestive elements for their malignant nature and for the differential diagnosis. Sonography has the capacity to clarify the nature of opaque lesions such as effusions, atelectasis, masses, and consolidations. Transthoracic ultrasound has received increased interest from chest Physicians in recent years as it has the advantages of bedside availability, absence of radiation, and guided aspiration of fluid-filled areas and solid tumors. Furthermore US allows percutaneous guided biopsies with lower risks compared with the radiological guiding methods (fluoroscopy and CT). Trransthoracic US can replace other imaging modalities of the chest and guide a variety of diagnostic and therapeutic procedures. Under real time US guidance, the success rate of transthoracic needle aspiration or biopsy (TNB) significantly increases, whereas the risk of complications is greatly reduced. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04741958
Study type Interventional
Source Beni-Suef University
Contact
Status Completed
Phase N/A
Start date September 12, 2020
Completion date December 1, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Completed NCT02909452 - Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04556344 - Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competencies of Patients Under Surveillance After Antineoplastic Treatment of Oesogastric or Bronchopulmonary Cancer N/A
Terminated NCT03306693 - Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers N/A
Completed NCT04751552 - Erector Spinae Block for Thoracoscopic Surgery N/A
Not yet recruiting NCT06104774 - The Effects of a Family-Centered Tai Chi Exercise on Lung Function and Mental Health of Patients After Thoracoscopic Surgery N/A
Completed NCT05770869 - mHealth ALIBIRD: A Digital Health Care Model N/A
Active, not recruiting NCT04589247 - Improving Cancer Symptom Management
Not yet recruiting NCT04133337 - Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC Phase 1/Phase 2
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Completed NCT02188563 - A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers N/A
Completed NCT03134872 - A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC Phase 3
Not yet recruiting NCT04371796 - Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC Phase 2
Completed NCT00437372 - Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients Phase 1
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04862780 - (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC Phase 1/Phase 2
Recruiting NCT04776447 - Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) Phase 2
Recruiting NCT05988736 - Comparison Between McGrath and Macintosh Laryngoscopes for DLT Intubation in Thoracic Surgery Patients. N/A
Not yet recruiting NCT06376084 - Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Active, not recruiting NCT04222972 - A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Phase 3